Delivery Order SPE2DR25D3301-SPE2DR26F19BS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $89,422.68 to AmerisourceBergen Drug Corp for Jemperli (venetoclax) 500 mg/10 mL vials on July 17, 2025, with completion expected by August 7, 2025. This firm fixed-price delivery order, issued without set-aside designation, leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999 through December 2026. The place of performance is...
- The Defense Logistics Agency has awarded a delivery order valued at $7,451.89 to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. This is a firm fixed-price, competitively awarded contract with no set-aside designation, due for completion by August 11, 2025. The awardee, headquartered in Conshohocken, Pennsylvania, will perform delivery from its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a $29,807.56 delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Jemperli 500 mg/10 ml vials. This is a firm fixed-price delivery order with an ultimate completion date of September 30, 2025, and represents a non-set-aside, competitively awarded contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this delivery at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Jemperli 500 mg/10 mL vials with a ceiling value of $14,903.78. This is a firm fixed price delivery order under a child contract with no set-aside designation, requiring performance and completion by August 29, 2025. The drug will be supplied to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate office. This...
- The Defense Logistics Agency awarded a delivery order valued at approximately $29.8K to AmerisourceBergen Drug Corp for the supply of Jemperli 500 mg/10 mL vials. The contract was competitively awarded without set-aside provisions and carries a firm fixed-price structure, with an ultimate completion date of September 23, 2025. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. Jemperli is a specialized pharmaceutical product used in oncology treatment,...
- The Defense Logistics Agency awarded a $29.8K delivery order to AmerisourceBergen Drug Corp on October 20, 2025, for the supply of Jemperli 500 mg/10 mL vials. This is a firm fixed-price, non-set-aside contract with a completion date of November 10, 2025, with performance conducted at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Jemperli 500 mg/10 mL vials with a ceiling value of $59,615.12 and firm fixed pricing. This is a competitive award with no set-aside designation, requiring completion by September 3, 2025. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger...
- The Defense Logistics Agency awarded a $37,259.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of JEMPERLI 500 mg/10 mL vials. This non-set-aside competitive award was issued on August 1, 2025, with an ultimate completion date of August 22, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. JEMPERLI is a specialized pharmaceutical product, and this order represents one of many...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order valued at $113,363.90 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of JEMPERLI 500 MG/10 ML VIAL 10ML pharmaceutical products. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $22,355.67 contract is for the supply of JEMPERLI 500 MG/10 ML VIAL 10ML, a pharmaceutical product. The award is not set aside and has an ultimate completion date of July 7, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- SPE2DR25D3301Indefinite Delivery Contract
- SPE2DR25D3301-SPE2DR26F19BSDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $23,559.45 to AmerisourceBergen Drug Corp for the supply of Jemperli (venetoclax) 500 mg/10 ml vials, with an ultimate completion date of December 29, 2025. The contract was competitively awarded without set-aside designation under a firm fixed-price delivery order mechanism. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. This comprehensive prime vendor agreement enables the contractor to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and other government healthcare systems. The pharmaceutical product being delivered under this award represents a component of the company's extensive federal medical supply portfolio encompassing specialty medications, brand-name and generic drugs, and specialized medical commodities across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $23.6k | 12/4/25 |